Lacquaniti eyes expansion

Share this article:

The selection process was described as extensive and exhaustive, but now that Mary Lacquaniti is settling into her new role as executive director of the Healthcare Marketing and Communications Council (HMC), she is focused on the future.
"This is very exciting," she said in an interview this week, noting that one of her priorities is to continue "to add value" for HMC's roughly 1,100 members. "We have some key volunteers [and] we have a series of new initiatives," she added. "We just want to expand those and make sure we are meeting the needs of our members."
Among the initiatives is HMC University, a new "framework" for the education platform and which aims to be a continuing resource for healthcare marketers throughout their career. "We want to see all of our educational initiatives on more of an educational platform," Lacquaniti said. "We want to make sure our existing programs remain current and we have a great group of volunteers taking great initiative."
The HMC University program is in development, and Lacquaniti said she anticipates more announcing more details HMC University programs in the next month.
Laquaniti served as HMC's associate director since 2001 and had joined the staff as a program manager in March 1999. In June she earned the Certified Association Executive credential form the American Society of Association Executives. Lacquaniti succeeded Richard Sawyer, who had held the top post at HMC since 1992.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...